Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
PDS Biotechnology
Biotech
PDS halts ph. 3 cancer therapy to focus on colorectal contender
PDS Biotechnology has called time on its phase 3 head and neck cancer therapy to channel resources to a metastatic colorectal cancer drug in phase 2.
James Waldron
Aug 13, 2026 9:55am
PDS reports 39 months OS in phase 2 head and neck cancer trial
Aug 25, 2025 9:00am
BridgeBio, Ipsen, George Medicines and more—Chutes & Ladders
May 3, 2024 8:30am
Pfizer's migraine market chief joins Apnimed—Chutes & Ladders
Jan 26, 2024 9:30am
Merck KGaA hands over IL-12 cancer med for up to $121M
Jan 3, 2023 2:17pm
